An in-depth analysis of the epidemiological patterns of TB/HIV co-infection is essential since it helps to target high-risk areas with effective control measures. The main objective of this study was to assess the spatial clustering of TB/HIV co-infection prevalence in Ethiopia for the year 2018 using district-level aggregated TB and HIV data obtained from the Ethiopian Federal Ministry of Health. The global Moran's index, Getis-Ord [Formula: see text] local statistic, and Bayesian spatial modeling techniques were applied to analyse the data. The result of the study shows that TB among people living with HIV (PLHIV) and HIV among TB patients prevalence were geographically heterogeneous. The highest prevalence of TB among PLHIV in 2018 was reported in the Gambella region (1.44%). The overall prevalence of TB among PLHIV in Ethiopia in the same year was 0.38% while the prevalence of HIV among TB patients was 6.88%. Both district-level prevalences of HIV among TB patients and TB among PLHIV were positively spatially autocorrelated, but the latter was not statistically significant. The local indicators of spatial analysis using the Getis-Ord statistic also identified hot-spots districts for both types of TB/HIV co-infection data. The results of Bayesian spatial logistic regression with spatially structured and unstructured random effects using the Besag, York, and Mollié prior showed that not all the heterogeneities in the prevalence of HIV among TB patients and TB among PLHIV were explained by the spatially structured random effects. This study expanded knowledge about the spatial clustering of TB among PLHIV and HIV among TB patients in Ethiopia at the district level in 2018. The findings provide information to health policymakers in the country to plan geographically targeted and integrated interventions to jointly control TB and HIV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035872 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283334 | PLOS |
AIDS Res Ther
January 2025
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
The global HIV epidemic remains a major public health challenge, with DTG playing a key role in ART regimens due to its efficacy and tolerability. This study evaluated virological outcomes and resistance mutations in patients on DTG in Mozambique through a retrospective cohort study in seven DREAM centers. Data from 29,601 patients (98.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Statistics, University of South Africa, c/o Christiaan de Wet Road & Pioneer Avenue, Private Bag X6, Florida, 1710, Johannesburg, South Africa.
Background: The aim of this paper was to evaluate the distribution of HIV and TB in Ethiopia during four years (2015-2018) at the district level, considering both spatial and temporal patterns.
Methods: Consolidated data on the count of TB case notifications and the number of patients with HIV for four years, 2015-2018, were provided by the Ethiopian Federal Ministry of Health. The data was analyzed using the Bayesian hierarchical approach, employing joint spatiotemporal modelling.
J Neurovirol
January 2025
Department of Pharmacology and Toxicology, Medical Sciences Campus, University of Puerto Rico, San Juan, 00936-5067, Puerto Rico.
The role of plasma exosomes from people living with HIV (PLWH) with HAND in the phenotypic profile of uninfected monocytes remains unknown. We hypothesized that these exosomes influence the CD14/CD16 phenotypical profile of uninfected monocytes in a time-dependent manner. Exosomes were collected via ultracentrifugation from the plasma of women living with HIV (WLWH) and healthy controls stratified according to their cognition into normal cognition (NC) or symptomatic neurocognitive impairment (SNI) groups.
View Article and Find Full Text PDFTravel Med Infect Dis
January 2025
Servicio de Infectología, Hospital Militar Central, Bogotá D.C., Colombia; Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá, D.C., Colombia. Electronic address:
Nature
January 2025
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Autologous chimeric antigen receptor (CAR) T cells are a genetically engineered therapy that is highly effective against B cell malignancies and multiple myeloma. However, the length and cost of personalized manufacturing limits access and leaves patients vulnerable to disease progression. Allogeneic cell therapies have the potential to increase patient access and improve treatment outcomes but are limited by immune rejection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!